NRx Pharmaceuticals (NRXP) Competitors $2.64 +0.11 (+4.35%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.71 +0.07 (+2.65%) As of 08/22/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRXP vs. GNFT, MDWD, RAPT, NLTX, OGI, EPRX, KRRO, TNYA, ENGN, and TILShould you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include GENFIT (GNFT), MediWound (MDWD), Rapt Therapeutics (RAPT), Neoleukin Therapeutics (NLTX), Organigram Global (OGI), Eupraxia Pharmaceuticals (EPRX), Korro Bio (KRRO), Tenaya Therapeutics (TNYA), enGene (ENGN), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry. NRx Pharmaceuticals vs. Its Competitors GENFIT MediWound Rapt Therapeutics Neoleukin Therapeutics Organigram Global Eupraxia Pharmaceuticals Korro Bio Tenaya Therapeutics enGene Instil Bio NRx Pharmaceuticals (NASDAQ:NRXP) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership. Which has more risk & volatility, NRXP or GNFT? NRx Pharmaceuticals has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, GENFIT has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Which has preferable valuation & earnings, NRXP or GNFT? GENFIT has higher revenue and earnings than NRx Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNRx PharmaceuticalsN/AN/A-$25.13M-$2.24-1.18GENFIT$76.77M2.81$1.63MN/AN/A Is NRXP or GNFT more profitable? Company Net Margins Return on Equity Return on Assets NRx PharmaceuticalsN/A N/A -550.94% GENFIT N/A N/A N/A Do analysts prefer NRXP or GNFT? NRx Pharmaceuticals currently has a consensus price target of $28.50, suggesting a potential upside of 979.55%. GENFIT has a consensus price target of $9.00, suggesting a potential upside of 108.53%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than GENFIT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to NRXP or GNFT? In the previous week, NRx Pharmaceuticals had 4 more articles in the media than GENFIT. MarketBeat recorded 14 mentions for NRx Pharmaceuticals and 10 mentions for GENFIT. GENFIT's average media sentiment score of 1.00 beat NRx Pharmaceuticals' score of -0.14 indicating that GENFIT is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral GENFIT 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in NRXP or GNFT? 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.2% of GENFIT shares are owned by institutional investors. 19.0% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 4.2% of GENFIT shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryNRx Pharmaceuticals beats GENFIT on 8 of the 12 factors compared between the two stocks. Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXP vs. The Competition Export to ExcelMetricNRx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.30M$2.53B$5.81B$9.76BDividend YieldN/A1.67%4.39%4.06%P/E Ratio-1.1822.9031.3626.05Price / SalesN/A516.56387.8788.42Price / CashN/A179.1038.0259.36Price / Book-1.475.939.536.60Net Income-$25.13M$31.83M$3.26B$265.65M7 Day Performance-8.65%1.89%2.14%2.00%1 Month Performance-11.71%1.62%3.22%0.46%1 Year Performance26.92%9.25%30.18%18.88% NRx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXPNRx Pharmaceuticals3.0978 of 5 stars$2.64+4.3%$28.50+979.5%+26.3%$52.30MN/A-1.182Earnings ReportAnalyst ForecastShort Interest ↓Gap UpGNFTGENFIT2.1585 of 5 stars$4.50+12.8%$13.00+188.9%-0.8%$199.51M$76.77M0.00120News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeMDWDMediWound1.4321 of 5 stars$17.60-2.8%$32.25+83.2%-5.1%$195.62M$20.22M-6.6780Analyst DowngradeRAPTRapt Therapeutics4.4396 of 5 stars$11.73-0.1%$21.57+83.9%-39.3%$194.15M$1.53M-0.8380NLTXNeoleukin TherapeuticsN/A$20.51+1.5%N/A-42.8%$192.75MN/A-6.5990High Trading VolumeOGIOrganigram Global0.382 of 5 stars$1.53+7.0%N/A-20.8%$191.66M$117.47M30.61860EPRXEupraxia Pharmaceuticals1.9635 of 5 stars$5.30-0.4%$11.00+107.5%+97.8%$191.42MN/A-6.2429News CoverageAnalyst ForecastGap UpKRROKorro Bio1.3239 of 5 stars$19.72-2.7%$86.83+340.3%-55.6%$190.26M$2.27M-2.0270TNYATenaya Therapeutics2.8079 of 5 stars$1.26+8.6%$6.25+396.0%-60.4%$189.05MN/A-1.31110Gap UpHigh Trading VolumeENGNenGene3.3172 of 5 stars$3.72+1.1%$23.29+526.0%-32.7%$188.07MN/A-2.2531News CoverageTILInstil Bio3.3709 of 5 stars$28.85+3.6%$119.00+312.5%+99.2%$187.94MN/A-2.23410 Related Companies and Tools Related Companies GENFIT Alternatives MediWound Alternatives Rapt Therapeutics Alternatives Neoleukin Therapeutics Alternatives Organigram Global Alternatives Eupraxia Pharmaceuticals Alternatives Korro Bio Alternatives Tenaya Therapeutics Alternatives enGene Alternatives Instil Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXP) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access